Aptose Biosciences Amends Acquisition Agreement, Extends Go-Private Transaction Deadline

summarizeSummary

This SC 13E3/A filing provides a material update to the ongoing going-private transaction where Aptose Biosciences Inc. is being acquired by HS North America Ltd. The key change is the amendment and restatement of the Arrangement Agreement to extend the outside date for the completion of the acquisition. While the core terms of the C$2.41 per share cash consideration remain, the extension of the deadline introduces a procedural delay. Investors should monitor for further updates regarding the new timeline and any potential implications for the deal's certainty. The company concurrently filed a definitive proxy statement, which contains comprehensive details about the transaction.

check_boxKey Events

• Acquisition Agreement Amended

  The Arrangement Agreement, initially dated November 18, 2025, has been amended and restated on February 23, 2026.

• Go-Private Transaction Deadline Extended

  The amendment specifically extends the outside date for the completion of the going-private Arrangement by HS North America Ltd.

• Definitive Proxy Statement Filed

  A definitive proxy statement (DEFM14A) was filed concurrently, providing comprehensive details about the transaction and incorporated by reference into this filing.

• Delisting and Deregistration Planned

  Upon completion of the Arrangement, Aptose Biosciences Inc. will become a wholly-owned indirect subsidiary, cease to be a reporting issuer, and its shares will be delisted from the Toronto Stock Exchange and OTC Markets.

auto_awesomeAnalysis

This SC 13E3/A filing provides a material update to the ongoing going-private transaction where Aptose Biosciences Inc. is being acquired by HS North America Ltd. The key change is the amendment and restatement of the Arrangement Agreement to extend the outside date for the completion of the acquisition. While the core terms of the C$2.41 per share cash consideration remain, the extension of the deadline introduces a procedural delay. Investors should monitor for further updates regarding the new timeline and any potential implications for the deal's certainty. The company concurrently filed a definitive proxy statement, which contains comprehensive details about the transaction.